JPWO2014104019A1 - 尿中ポドサイトの検出方法 - Google Patents
尿中ポドサイトの検出方法 Download PDFInfo
- Publication number
- JPWO2014104019A1 JPWO2014104019A1 JP2014554455A JP2014554455A JPWO2014104019A1 JP WO2014104019 A1 JPWO2014104019 A1 JP WO2014104019A1 JP 2014554455 A JP2014554455 A JP 2014554455A JP 2014554455 A JP2014554455 A JP 2014554455A JP WO2014104019 A1 JPWO2014104019 A1 JP WO2014104019A1
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- podocytes
- bound
- urine
- insoluble carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000557 podocyte Anatomy 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000002485 urinary effect Effects 0.000 title claims abstract description 31
- 210000002700 urine Anatomy 0.000 claims abstract description 62
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 230000003287 optical effect Effects 0.000 claims abstract description 19
- 239000004816 latex Substances 0.000 claims description 34
- 229920000126 latex Polymers 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 239000013049 sediment Substances 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000004793 Polystyrene Substances 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 229920002223 polystyrene Polymers 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 description 20
- 238000001514 detection method Methods 0.000 description 16
- 208000020832 chronic kidney disease Diseases 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 102000004401 podocalyxin Human genes 0.000 description 8
- 108090000917 podocalyxin Proteins 0.000 description 8
- 201000008383 nephritis Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000022461 Glomerular disease Diseases 0.000 description 5
- 231100000852 glomerular disease Toxicity 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 208000028208 end stage renal disease Diseases 0.000 description 4
- 201000000523 end stage renal failure Diseases 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- -1 polypropylene Polymers 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000006453 Class 3 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 description 2
- 108010044214 Class 3 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 241000238413 Octopus Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010038357 Renal amyloidosis Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000007891 familial visceral amyloidosis Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000001039 kidney glomerulus Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
1.以下の工程を含む、尿中ポドサイトを検出する方法:
(1)不溶性担体が結合した、ポドサイトの表面に特異的に発現するタンパク質を認識する抗体を準備する工程;
(2)不溶性担体の結合した抗体を、被験者の尿検体に接触させる工程;
(3)不溶性担体の結合した抗体と接触させた尿検体を、光学顕微鏡により観察し、ポドサイトを計測する工程。
2.前記不溶性担体がポリスチレンラテックス粒子である、前項1に記載の尿中ポドサイトを検出する方法。
3.ポドサイトの表面に特異的に発現するタンパク質を認識する抗体が、抗ポドカリキシン抗体である、前項1または2に記載の尿中ポドサイトを検出する方法。
4.ポドサイトの計測数が1個/mL以上である場合に、腎障害の可能性があると判定される、前項1〜3のいずれか1に記載の尿中ポドサイトを検出する方法。
5.尿検体が、尿沈渣である、前項1〜4のいずれか1に記載の尿中のポドサイトを検出する方法。
6.以下の試薬を含む、前項1〜5のいずれか1に記載の尿中ポドサイトを検出する方法に用いられる、尿中ポドサイトを検出するための試薬キット:
(a)不溶性担体が結合した、ポドサイト特異的に細胞表面に発現するタンパク質を特異的に認識する抗体を含む試薬;
(b)光学顕微鏡での細胞観察に用いられる試薬および器具のうち、少なくとも1つ。
(1)不溶性担体が結合した、ポドサイトの表面に特異的に発現するタンパク質を認識する抗体(以下単に「不溶性担体の結合した抗体」と称することもある)を準備する工程;
(2)不溶性担体の結合した抗体を、被験者の尿検体に接触させる工程;
(3)不溶性担体の結合した抗体と接触させた尿検体を、光学顕微鏡により観察し、ポドサイトを計測する工程。
(a)不溶性担体が結合した、ポドサイトの表面に特異的に発現するタンパク質を認識する抗体を含む試薬。
(b)光学顕微鏡での細胞観察に用いられる試薬および器具のうち、少なくとも1つ。
(b)光学顕微鏡での細胞観察に用いられる試薬および器具としては、尿の処理に用いられる処理液、スライドグラス、ポジティブコントロール、ポドサイト観察例、採尿スピッツ等が例示される。
下記の手順により、蛍光抗体法を行った。
(1)早朝新鮮尿30mLを、尿細胞保存液20mLの入っているウリキープ5D(武藤化学株式会社)に保存した。(所要時間1〜2分間)
(2)スライドグラス上に、サイトスピンにてオートスメアサンプルを作製した(所要時間10分間)。
(3)作製したオートスメアサンプルを風乾させた(所要時間1〜2時間)。
(4)風乾させたサンプルと抗ポドカリキシン抗体とを、室温で1時間静置して反応させた(所要時間1時間)。
(5)反応後、スライドグラスをPBSで3回洗浄した(所要時間5分間)
(6)スライドグラス上のサンプルと、FITC標識抗マウスIgGとを、室温で1時間静置して反応させた(所要時間1時間)
(7)反応後、スライドグラスをPBSで3回洗浄した(所要時間5分間)
(8)蛍光顕微鏡を用いて、スライドグラス上のサンプルを100倍で検鏡した。
(ラテックス粒子結合抗ポドカリキシン抗体の作製)
TechNote 205, Rev.003, Active: 30/Mar/02 "Covalent Coupling", Bangs Laboratories Inc.を参照して、ラテックス粒子結合抗ポドカリキシン抗体を作製した。
下記の手順により、上記ラテックス粒子結合抗ポドカリキシン抗体を用いた検出方法を行った。
(1)早朝新鮮尿9mLを、2M TES-NaOHに0.2M EDTAを含む溶液(pH7.0)1mLと混合した。(所要時間1〜2分間)
(2)混合した試料を、遠心分離(1710g×5分間)後、上清を除去し、ペレットを得た。(所要時間7〜8分間)
(3)ペレットに、蒸留水を7.5mL添加して混合し、その後直ぐに400mM TES-NaOHに40mM EDTAに含む溶液(pH7.0)7.5mLを添加した。(所要時間1〜2分間)
なお蒸留水を加える理由は、尿沈渣中の赤血球を溶血させるためである。
(4)混合した試料を、遠心分離(1710g×5分間)後、上清を除去し、ペレットとして尿沈渣を得た。(所要時間7〜8分間)
(5)尿沈渣に、ラテックス粒子結合抗ポドカリキシン抗体45μL(ラテックス粒子濃度が0.1%(重量%))を添加して、室温で90分間振盪させて反応させた(所要時間90分間)。
(6)反応後のサンプルをスライドグラスに載せて、光学顕微鏡により100倍で検鏡した。
Claims (6)
- 以下の工程を含む、尿中ポドサイトを検出する方法:
(1)不溶性担体が結合した、ポドサイトの表面に特異的に発現するタンパク質を認識する抗体を準備する工程;
(2)不溶性担体の結合した抗体を、被験者の尿検体に接触させる工程;
(3)不溶性担体の結合した抗体と接触させた尿検体を、光学顕微鏡により観察し、ポドサイトを計測する工程。 - 前記不溶性担体がポリスチレンラテックス粒子である、請求項1に記載の尿中ポドサイトを検出する方法。
- ポドサイトの表面に特異的に発現するタンパク質を認識する抗体が、抗ポドカリキシン抗体である、請求項1または2に記載の尿中ポドサイトを検出する方法。
- ポドサイトの計測数が1個/mL以上である場合に、腎障害の可能性があると判定される、請求項1〜3のいずれか1に記載の尿中ポドサイトを検出する方法。
- 尿検体が、尿沈渣である、請求項1〜4のいずれか1に記載の尿中のポドサイトを検出する方法。
- 以下の試薬を含む、請求項1〜5のいずれか1に記載の尿中ポドサイトを検出する方法に用いられる、尿中ポドサイトを検出するための試薬キット:
(a)不溶性担体が結合した、ポドサイトの表面に特異的に発現するタンパク質を認識する抗体を含む試薬;
(b)光学顕微鏡での細胞観察に用いられる試薬および器具のうち、少なくとも1つ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012282394 | 2012-12-26 | ||
JP2012282394 | 2012-12-26 | ||
PCT/JP2013/084490 WO2014104019A1 (ja) | 2012-12-26 | 2013-12-24 | 尿中ポドサイトの検出方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2014104019A1 true JPWO2014104019A1 (ja) | 2017-01-12 |
JP6310861B2 JP6310861B2 (ja) | 2018-04-11 |
Family
ID=51021100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014554455A Active JP6310861B2 (ja) | 2012-12-26 | 2013-12-24 | 尿中ポドサイトの検出方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20160003820A1 (ja) |
EP (1) | EP2940471B1 (ja) |
JP (1) | JP6310861B2 (ja) |
WO (1) | WO2014104019A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6751080B2 (ja) * | 2015-04-22 | 2020-09-02 | 原 正則 | 尿中ポドサイト数を推定する方法 |
WO2018177949A1 (en) * | 2017-03-25 | 2018-10-04 | Charité-Universitätsmedizin Berlin | Urine flow cytometry as biomarker of renal diseases |
EP3385711A1 (en) * | 2017-04-05 | 2018-10-10 | Charité - Universitätsmedizin Berlin | Urine flow cytometry as biomarker of renal diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63255660A (ja) * | 1987-04-11 | 1988-10-21 | Hitachi Ltd | 細胞測定法 |
WO2002037099A1 (fr) * | 2000-10-27 | 2002-05-10 | International Reagents Corporation | Procede de diagnostic de la nephropathie |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4421896A (en) * | 1979-11-13 | 1983-12-20 | The Dow Chemical Company | Method of coupling a protein to a polymer particle containing hydrazide groups in a polymer latex and the products formed therefrom |
US4426295A (en) * | 1981-09-28 | 1984-01-17 | Evans Deborah A | Cell suspension chamber process |
NO308755B1 (no) * | 1996-12-20 | 2000-10-23 | Iystein Fodstad | FremgangsmÕte til karakterisering av unormale celler, anvendelse og sett for utførelse av fremgangsmÕten |
US20050250091A1 (en) * | 2004-05-05 | 2005-11-10 | Chemlmage Corporation | Raman molecular imaging for detection of bladder cancer |
JP5515740B2 (ja) * | 2007-09-27 | 2014-06-11 | 国立大学法人 新潟大学 | 尿中タンパク質定量用の尿前処理剤、尿前処理方法、及び尿中タンパク質定量方法。 |
EP2517014B1 (en) * | 2009-12-21 | 2014-11-19 | Mayo Foundation For Medical Education And Research | Early marker of proteinuria in patients treated with an anti-vegf treatment |
-
2013
- 2013-12-24 WO PCT/JP2013/084490 patent/WO2014104019A1/ja active Application Filing
- 2013-12-24 JP JP2014554455A patent/JP6310861B2/ja active Active
- 2013-12-24 EP EP13868804.9A patent/EP2940471B1/en active Active
-
2015
- 2015-06-24 US US14/748,889 patent/US20160003820A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63255660A (ja) * | 1987-04-11 | 1988-10-21 | Hitachi Ltd | 細胞測定法 |
WO2002037099A1 (fr) * | 2000-10-27 | 2002-05-10 | International Reagents Corporation | Procede de diagnostic de la nephropathie |
US20040058395A1 (en) * | 2000-10-27 | 2004-03-25 | Masanori Hara | Method of diagnosing nephropathy |
Non-Patent Citations (3)
Title |
---|
原正則ほか: "ルーチン尿沈渣検査による尿中Podocyte検出の試み", 日本腎臓学会誌, vol. 53, no. 3, JPN6014012667, 25 May 2011 (2011-05-25), pages 446, ISSN: 0003726089 * |
原正則ほか: "光学顕微鏡を用いた尿中Podocyte(Pod)の新しい検出法-抗体結合ラテックス粒子を用いた試み-", 日本腎臓学会誌, vol. 55, no. 6, JPN6014012666, 25 August 2013 (2013-08-25), pages 1054, ISSN: 0003726088 * |
黒澤芳子: "尿中ポドサイト検査", 医学検査, vol. 49, no. 4, JPN6014012665, 25 April 2000 (2000-04-25), pages 349, ISSN: 0003726090 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014104019A1 (ja) | 2014-07-03 |
EP2940471B1 (en) | 2019-09-18 |
EP2940471A4 (en) | 2016-10-05 |
US20160003820A1 (en) | 2016-01-07 |
JP6310861B2 (ja) | 2018-04-11 |
EP2940471A1 (en) | 2015-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dong et al. | Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium | |
US10908152B2 (en) | Paper based diagnostic test | |
Obeid et al. | Development of a NanoBioAnalytical platform for" on-chip" qualification and quantification of platelet-derived microparticles | |
JP6485759B2 (ja) | 末梢循環腫瘍細胞単位の悪性度の検出方法及びそのキット | |
TWI475229B (zh) | A reagent group for transfusion test and its test method | |
JP6310861B2 (ja) | 尿中ポドサイトの検出方法 | |
Van Beers et al. | Detection of anti-neutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence | |
JP6893639B2 (ja) | がんの判定方法、がんの判定のための装置及びコンピュータプログラム | |
Bystryak et al. | A flow-through cell counting assay for point-of-care enumeration of CD4 T-cells | |
KR102172016B1 (ko) | 항-cyfra21-1 자가항체-항원 결합체 및 cyfra21-1 항원 마커의 검출방법 및 이들 마커의 비율을 이용한 폐암 진단키트 | |
WO2016125243A1 (ja) | エクソソーム測定方法及びエクソソーム抽出方法 | |
US20120040850A1 (en) | Methods for Diagnosis and Assessment of Autoimmune Disorders | |
CA2486119A1 (en) | Method of isolating an endothelial cell and method of donor specific crossmatching | |
JP5017596B2 (ja) | 凝集検査方法 | |
WO2019069980A1 (ja) | 大腸癌の検出方法 | |
Chong et al. | Circulating tumor cell detection in lung cancer animal model | |
JP2010286375A (ja) | 重症薬疹易罹患性診断用マーカー、重症薬疹易罹患性の診断方法および重症薬疹易罹患性診断用キット | |
JP5844825B2 (ja) | 検出対象の検出及び定量のための方法及びキット | |
US20240077479A1 (en) | Detection system and method for the migrating cell | |
JP2004177402A (ja) | 特異結合反応測定方法、それに用いる試薬キットおよび特異結合反応測定装置 | |
JP2668448B2 (ja) | 糖尿病性腎症診断のための尿中の蛋白量判定方法および感作ラテックス | |
JP2004309477A (ja) | 抗体測定方法 | |
JP4458887B2 (ja) | ボルナ病ウイルス検出抗原及び試薬 | |
WO2017204208A1 (ja) | Smnタンパク質の核内構造体の発現解析方法 | |
WO2021099545A1 (en) | Nanoparticle tracking analysis as a biomarker tool in autoimmune diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170810 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180206 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180227 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180319 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6310861 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |